Page 140 | Certara

Publication

Enabling Warp Speed Using the Hypervelocity Innovation Model: A Blue Print for Drug Development in Pandemics

Pharmaceutical R&D is organized around prioritized investments, delivering on assets with the greatest return of…

CertaraSeptember 28, 2020

On-Demand Webinar

Payment Pressures in U.S. Specialty: Status quo and outlook for future financing

To allow for the optimal positioning of your product, portfolio, or company, it is critical…

CertaraSeptember 15, 2020

Announcement

New Pinnacle 21 Community Validation Engine: FDA (1907.2)

In August 2020, we released our new Pinnacle 21 validation engine “FDA (1907.2)” for preparing…

CertaraSeptember 13, 2020

Blog

Formatting Annotated Case Report Forms (aCRFs): Document properties, bookmarking and table of contents

Discover essential tips for formatting annotated CRFs, from dual bookmarking to document properties. Read the…

CertaraSeptember 10, 2020

Fact Sheet

Secondary Intelligence

Predicts off-target risks, streamlining secondary pharmacology analysis for safer drug development.

CertaraSeptember 4, 2020

On-Demand Webinar

Exploring Common CDISC ADaM Dataset Conformance Findings

What you need to know when validating your CDISC ADAM datasets During the regulatory review…

CertaraSeptember 3, 2020

Publication

Clinical trials of disease stages in COVID 19: complicated and often misinterpreted

As of July 28, 2020, 1840 clinical trials were registered globally, with 1001 clinical trials…

CertaraAugust 22, 2020

Publication

Accelerating Clinical Evaluation of Repurposed Combination Therapies for COVID-19

As the global COVID-19 pandemic continues, unabated and clinical trials demonstrate limited effective pharmaceutical interventions,…

CertaraAugust 22, 2020

Case Study

Arvinas Selects Certara’s D360 to Advance Speed and Efficiency of Discovery Research

In February 2020, we announced that Certara’s discovery research relationship with Arvinas had expanded to…

CertaraAugust 21, 2020

Fact Sheet

Regulatory Operations and Submission Leadership

Expert support across the submission lifecycle, using advanced eCTD technology to accelerate timelines, reduce risk,…

CertaraAugust 13, 2020

Enabling Warp Speed Using the Hypervelocity Innovation Model: A Blue Print for Drug Development in Pandemics

Payment Pressures in U.S. Specialty: Status quo and outlook for future financing

New Pinnacle 21 Community Validation Engine: FDA (1907.2)

Formatting Annotated Case Report Forms (aCRFs): Document properties, bookmarking and table of contents

Secondary Intelligence

Exploring Common CDISC ADaM Dataset Conformance Findings

Clinical trials of disease stages in COVID 19: complicated and often misinterpreted

Accelerating Clinical Evaluation of Repurposed Combination Therapies for COVID-19

Arvinas Selects Certara’s D360 to Advance Speed and Efficiency of Discovery Research

Regulatory Operations and Submission Leadership

Newsletter sign up

Quick links

Solutions

Contact